Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe

Real-world data (RWD) offers the possibility to derive novel insights on the use and performance of medicines in everyday clinical use, complementing rather than competing with evidence from randomized control trials. While Europe is rich in healthcare data, its heterogeneous nature brings operational, technical, and methodological challenges. We present a number of potential solutions to address the full spectrum of regulatory use cases and emphasize the importance of early planning of data collection.

[1]  Peter Arlett,et al.  Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works , 2017, Drug Safety.

[2]  D. Morales,et al.  Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerations , 2017, British journal of clinical pharmacology.

[3]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[4]  Thomas Goedecke,et al.  Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation , 2018, BMJ Open.

[5]  G. Mazzaglia,et al.  Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs , 2017, Drug Safety.

[6]  John P. McCrae,et al.  Monitoring safety in a phase III real‐world effectiveness trial: use of novel methodology in the Salford Lung Study , 2016, Pharmacoepidemiology and drug safety.

[7]  E. Skovlund,et al.  The use of real-world data in cancer drug development. , 2018, European journal of cancer.

[8]  Karl Broich,et al.  Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals? , 2018, Clinical pharmacology and therapeutics.

[9]  Olaf Klungel,et al.  Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  Xavier Kurz,et al.  Multi‐centre, multi‐database studies with common protocols: lessons learnt from the IMI PROTECT project , 2016, Pharmacoepidemiology and drug safety.

[11]  Olaf Klungel,et al.  Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0 , 2017, Pharmacoepidemiology and drug safety.